BICO adds new light-based 3D bioprinting technology to its portfolio through the acquisition of Allegro 3D

Model D Bioprinter - Allegro 3D

BICO Bioprinting just strengthens its position on the bioprinting market by acquiring all the shares in San Diego-based Allegro 3D Inc. (“Allegro 3D”) for an up-front enterprise value of USD 6 million. The company already has a robust portfolio of bioprinters which include extrusion based, 2PP and DLP technologies.

The new acquisition will greatly benefit the shareholders who could receive USD 5 million in an earnout payment contingent on Allegro 3D’s financial performance in the coming two years.

The entire purchase price will be paid in cash. Allegro 3D’s patented light-based printing technology will be commercialized by CELLINK and is a strong complement to the existing offering of application-tailored products, as the technology will allow customers greater ability to increase precision and scale their output of bio-fabricated constructs for regenerative medicine and drug discovery purposes.

The acquisition of Allegro 3D is in-line with our M&A strategy of add-on acquisitions where Allegro 3D complements CELLINK’s product portfolio strongly and can quickly be integrated into the current product offering and commercialization infrastructure.” comments BICO Head of M&A Jacob Thordenberg.

Allegro is an expert in the field of Digital Light Processing (DLP)-based printing. The Allegro 3D portfolio enables high precision and high speed bioprinting that is tailored for multi-well printing, providing life science companies the features needed for developing tissue constructs for regenerative medicine and drug testing workflows.

The acquisition is in line with BICO’s commercial agenda to provide technologies and sustainable solutions that bring us closer to a world where on-demand tissue is a reality, reducing the dependency on animal models. With Allegro 3D, BICO continues to add complementary bioprinting methods to the group. Adding to the CELLINK portfolio enables the company to strengthen its position as the global leader in providing bioprinters. With a robust portfolio of extrusion, 2PP and DLP printers, Allegro 3D’s patented printing technology is a strong complement to CELLINK’s existing offer of application-tailored products.

The company will remain an independent entity but will be integrated into the commercial structure of global bioprinting leader, CELLINK, another company in the BICO bioprinting business area.

 

 

Remember, you can post job opportunities in the AM Industry on 3D ADEPT Media free of charge or look for a job via our job board. Make sure to follow us on our social networks and subscribe to our weekly newsletter : FacebookTwitterLinkedIn & Instagram ! If you want to be featured in the next issue of our digital magazine or if you hear a story that needs to be heard, make sure to send it to contact@3dadept.com